|
|
Post by sla55 on Apr 25, 2019 8:59:30 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-scientific-data-28th-annual-scientific-andWESTLAKE VILLAGE, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented in an e-poster presentation on Thursday, April 25, 2019 at the 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019). “These data demonstrate that Afrezza’s ultra-rapid onset uniquely affects early post-prandial glucose levels and other measures of mealtime glycemic control,” stated Dr. David Kendall, Chief Medical Officer of MannKind. Poster Presentation Highlights Title: Ultra-rapid Profile of Technosphere® Insulin Inhalation Powder Mimics Time-Action Profile of Physiologic Absorption of Glucose From Mixed-Meal Tolerance Tests in Type 2 Diabetes AACE 2019 Thursday, April 25th (1:30-2:00pm Poster Presentation Area, Monitor 14) Presenter: David Kendall, MD, Chief Medical Officer, MannKind Corporation Highlights: Compared to insulin lispro, the ultra-rapid absorption of Afrezza provides significantly better control of early post-prandial glucose levels due to an earlier increase in glucose disposal and a faster suppression of endogenous glucose production. The duration of this effect is dose dependent. Compared to insulin lispro, Afrezza was associated with lower postprandial glucagon and C-peptide levels and produced a faster decrease in free fatty acid levels. The ultra-rapid profile of Afrezza closely approximates the time-action profile of physiologic insulin needs after a meal in patients with Type 2 Diabetes. About AACE Annual Meeting The AACE 2019 conference is an opportunity for healthcare professionals specializing in endocrinology, diabetes, and metabolism to gather to discuss the latest scientific advancements and best practices for enhancing patient care, and enjoy educational sessions led by the world's most respected endocrine clinicians.
|
|
|
|
Post by #NoMoreNeedles on Apr 25, 2019 9:07:29 GMT -5
|
|
|
|
Post by nemzter on Apr 25, 2019 9:52:27 GMT -5
investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-scientific-data-28th-annual-scientific-andWESTLAKE VILLAGE, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be presented in an e-poster presentation on Thursday, April 25, 2019 at the 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019). “These data demonstrate that Afrezza’s ultra-rapid onset uniquely affects early post-prandial glucose levels and other measures of mealtime glycemic control,” stated Dr. David Kendall, Chief Medical Officer of MannKind. Poster Presentation Highlights Title: Ultra-rapid Profile of Technosphere® Insulin Inhalation Powder Mimics Time-Action Profile of Physiologic Absorption of Glucose From Mixed-Meal Tolerance Tests in Type 2 Diabetes AACE 2019 Thursday, April 25th ( 1:30-2:00pm Poster Presentation Area, Monitor 14) Presenter: David Kendall, MD, Chief Medical Officer, MannKind Corporation Highlights: Compared to insulin lispro, the ultra-rapid absorption of Afrezza provides significantly better control of early post-prandial glucose levels due to an earlier increase in glucose disposal and a faster suppression of endogenous glucose production. The duration of this effect is dose dependent. Compared to insulin lispro, Afrezza was associated with lower postprandial glucagon and C-peptide levels and produced a faster decrease in free fatty acid levels. The ultra-rapid profile of Afrezza closely approximates the time-action profile of physiologic insulin needs after a meal in patients with Type 2 Diabetes. About AACE Annual Meeting The AACE 2019 conference is an opportunity for healthcare professionals specializing in endocrinology, diabetes, and metabolism to gather to discuss the latest scientific advancements and best practices for enhancing patient care, and enjoy educational sessions led by the world's most respected endocrine clinicians.
I hope we have more sessions, and that they're ALOT more than 30 minutes.
|
|
|
|
Post by centralcoastinvestor on Apr 25, 2019 10:26:27 GMT -5
This data and presentation is exactly what Dr. Kendall promised he would deliver. Is it flashy or market moving? Nope. However, the consistent flow of sound, well researched papers presented at events like this help continue to build a solid foundation for doctor and insurance acceptance. Dr. Kendall knows what it takes to establish Afrezza to the medical community. So glad to see him do it again.
|
|
|
|
Post by #NoMoreNeedles on Apr 25, 2019 10:45:14 GMT -5
So far he hasn’t published in any peer reviewed high impact medical journals!
|
|
|
|
Post by centralcoastinvestor on Apr 25, 2019 10:54:13 GMT -5
So far he hasn’t published in any peer reviewed high impact medical journals! It is my understanding that those take time to accomplish. I am sure he is trying to get that done but it is no easy task. I will certainly celebrate publication in a peer reviewed medical journal when that time comes. |
|
|
|
Post by bones1026 on Apr 25, 2019 11:35:56 GMT -5
This data and presentation is exactly what Dr. Kendall promised he would deliver. Is it flashy or market moving? Nope. However, the consistent flow of sound, well researched papers presented at events like this help continue to build a solid foundation for doctor and insurance acceptance. Dr. Kendall knows what it takes to establish Afrezza to the medical community. So glad to see him do it again. ANY other bio company would be up 20% on this news...MM’s have complete control |
|
|
|
Post by uvula on Apr 25, 2019 11:41:41 GMT -5
It's a poster session at a conference. It's good for mnkd but hardly a big event for a big bio company.
|
|
|
|
Post by bones1026 on Apr 25, 2019 12:07:31 GMT -5
It's a poster session at a conference. It's good for mnkd but hardly a big event for a big bio company. Big bio company? We’re not even a 300M MC...and the fact that we have clinical studies proven why we should be the one and only ULTRA RAPID mealtime insulin on the market, would qualify as a pretty big deal for a “penny stock” |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 25, 2019 12:10:45 GMT -5
It's a poster session at a conference. It's good for mnkd but hardly a big event for a big bio company. Big bio company? We’re not even a 300M MC...and the fact that we have clinical studies proven why we should be the one and only ULTRA RAPID mealtime insulin on the market, would qualify as a pretty big deal for a “penny stock” Very good point. |
|
|
|
Post by bones1026 on Apr 25, 2019 12:12:08 GMT -5
Just to piggy back on that as well, you may be right that it doesn’t warrant a 20% increase, but I can bet you money the SP wouldn’t be absolutely pinned at a 3% raise for the entire day
|
|
|
|
Post by awesomo on Apr 25, 2019 12:59:22 GMT -5
Afrezza is long past the phase of hype and potential, Wall Street only cares about results at this point. That's the only thing that will move the needle.
|
|
|
|
Post by hellodolly on Apr 25, 2019 13:05:45 GMT -5
This data and presentation is exactly what Dr. Kendall promised he would deliver. Is it flashy or market moving? Nope. However, the consistent flow of sound, well researched papers presented at events like this help continue to build a solid foundation for doctor and insurance acceptance. Dr. Kendall knows what it takes to establish Afrezza to the medical community. So glad to see him do it again. ANY other bio company would be up 20% on this news...MM’s have complete control NOPE! I can give you dozens of announcements that not only don't result in a pop, but have resulted in a drop on positive news. |
|
|
|
Post by uvula on Apr 25, 2019 13:10:26 GMT -5
It's a poster session at a conference. It's good for mnkd but hardly a big event for a big bio company. Big bio company? We’re not even a 300M MC...and the fact that we have clinical studies proven why we should be the one and only ULTRA RAPID mealtime insulin on the market, would qualify as a pretty big deal for a “penny stock” bones, I was replying to your comment. I never called mnkd a big bio company. |
|
|
|
Post by sellhighdrinklow on Apr 25, 2019 13:23:10 GMT -5
Need some volume BUYS of MNKD. There have been delayed buys after MNKD news (label change in Oct '17)
|
|
